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p= 0.03), use of 3rd generation SU (OR= 0.86 [0.78 - 0.95]; p= 0.002), and chronic renal 
disease (OR= 1.34 [1.07 - 1.67]; p= 0.01). ConClusions: In conclusion, multiple fac-
tors, including efficacy and hypoglycemia, are associated with discontinuation of 
SU treatment after insulin initiation.
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objeCtives: Sulfonylurea (SU) may be discontinued or down-titrated due to 
hypoglycemia. Hypoglycemia may be more concerning for patients not receiving 
aggressive efficacy-driven treatment such as the dual-therapy of SU and insulin. A 
retrospective cohort study using the MarketScan database was conducted to assess 
the association between hypoglycemia and therapy changes (discontinuation or 
down-titration) among adults receiving SU therapy without insulin. Methods: 
Patients with the first SU prescription (Rx) (index date) in 2009-2011, ≥ 18 years 
of age on the index date, and with ≥ 1 year continuous enrollment pre- and post-
index were included. Patients were excluded if they received insulin within the 
1-year pre- or post-index, had ≥ 2 SUs on the index date, or had type 1, gestational 
or secondary diabetes. Therapy changes were determined during the 1-year post-
index period. Discontinuation occurred when consecutive SU fills were ≥ 90 days 
apart. Down-titration occurred when an SU fill had a lower equivalent dose than 
the index dose. Hypoglycemic events were identified using ICD-9 code between the 
index date and the therapy change or the end of the 1-year post-index period. Cox 
regression was used to evaluate the association between hypoglycemic events and 
therapy changes. Results: 97,570 patients were included in the study, of which 
50,854 (52.1%) experienced therapy changes within 1-year post-index. Patients with 
hypoglycemic events were at significantly higher risk for therapy changes (HR= 
1.86 [1.75, 1.97]; p< . 01). Specifically, they were 197% more likely to down-titrate 
(HR= 2.97 [2.53, 3.46]; p< . 01) and 80% more likely to discontinue (HR= 1.80 [1.69, 1.92]; 
p< . 01). ConClusions: Post-index hypoglycemic events are significantly associ-
ated with therapy changes among patients receiving SU without insulin, especially 
down-titration.
PDB122
guIDelIne aDHerence anD control of DIaBetes mellItus wItH  
co-morBIDItIes In a tertIary-care HosPItal In malaysIa
Iqbal M.Z.1, Iqbal M.S.1, Khan A.H.2, Sulaiman S.A.2, Iqbal M.W.3
1Department of Clinical Pharmacy, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 
2Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 
Pulau Pinang,,,, Malaysia, 3Faculty of Law, Universiti Malaya,, Kualalumpur, Malaysia
objeCtives: To evaluate doctors’ adherence to Malaysian Clinical Practice 
Guideline (CPG) 2009 in the management of diabetes mellitus with co-morbidities 
in Malaysia. Methods: Cross-sectional study was done at a tertiary-care hospital 
in Malaysia. Total 51 physicians and 1020 patients’ prescriptions written by same 
physicians (20 prescriptions per physician) were analyzed. All patients had diabetes 
mellitus with co-morbidities. Depending on the recommendations of CPG 2009, 
the prescriptions were clustered as adherent and non-adherent prescriptions. All 
obtained data were analyzed using descriptive and inferential statistics. Results: A 
statistically significant negative association (Ф= 0.094, p-value= 0.003) was observed 
between diabetes mellitus control and co-morbidities. CPG adherent had statisti-
cally weak negative association (Ф= - 0.081, p-value= 0.010) with patients having 
co-morbidities (41.6%). No statistically significant association was observed between 
CPG adherence and any other co-morbidity. Majority of the patients received guide-
lines-compliant pharmacotherapy. The overall good level of physician adherence 
with CPG 2009 was observed in the management of diabetes mellitus with co-
morbidities. ConClusions: The study explored several features of prescription 
pattern of the physicians involved in the management of diabetes mellitus with 
co-morbidities and recognized the need for improvement in their prescription pat-
tern for treating the diabetes mellitus.
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objeCtives: Diabetes is associated with a number of microvascular and macrovas-
cular complications. Diabetic macular edema (DME) is one of these complications 
and is among the leading causes of vision impairment. However, little data exists 
as to the patient-related burden of DME in Europe and the aim of the current study 
was to address this gap. Methods: Data from the 2013 5EU (France, Germany, Italy, 
Spain, and UK) National Health and Wellness Survey (NHWS) were used (N= 62,000). 
The NHWS is a patient-reported survey administered to a demographically rep-
resentative sample of adults (with respect to age, sex, and region). Patients who 
reported experiencing DME were compared with a propensity-scored matched con-
trol group of patients with diabetes but without DME. Matching variables included 
demographics, comorbidities (Charlson comorbidity index [CCI]), and diabetes 
history. Post-match, patients with DME and matched controls were compared on 
health outcomes (SF-36v2, Work Productivity and Activity Impairment, and self-
reported health care resource utilization) using general linear models. Results: 
4,088 patients reported diabetes (6.6%). Of these, 296 (7.2%) reported having DME. 
Patients with DME were more likely to have type 1 diabetes (26.4% vs. 8.5%), had been 
diagnosed with diabetes for longer (54.4% vs. 20.7% were diagnosed 16+ years), were 
more likely to use insulin (68.6% vs. 27.3%), and had a greater comorbidity burden 
(CCI = 2.2 vs. 1.6) (all p< .05), among other differences. After matching on these 
variables, patients with DME (n= 286) reported significantly worse physical health 
status (PCS: 41.1 vs. 43.2), greater overall work impairment (36.2% vs. 25.64%), and 
objeCtives: HIPOS-ER is the first national Hypoglycemia study in Portugal col-
lecting specific resource data directly in the hospitals. Here we aim to describe 
the average cost of severe hypoglycemic event by anti-hyperglycemic agent (AHA) 
class. Methods: The study was conducted in 7 centers in mainland Portugal for 
a period of 12 months (Jan13-Jan14). Patient level data and resource utilization 
were collected. Unit costs for 2014 were extracted from official sources. Regarding 
emergency room (ER) attendance, costs were calculated multiplying resource use by 
corresponding unit costs. For hospitalization, length of stay was multiplied by daily 
cost obtained through hospital account record. AHA therapy classes were: Group 1 
(insulin), Group 2 (secretagogue), Group 3 (oral AHA excluding secretagogue), and 
Group 4 (at least one insulin and one secretagogue). Results: 238 patients were 
enrolled and 105 (44%) were hospitalized. The distribution based on AHA therapy: 
55% (131) Group 1, 32% (75) Group 2, 7% (16) Group 3 and 7% (16) Group 4. After ER 
episode, Group 2 patients were more often hospitalized versus Group 1 (71% vs. 29%; 
p< 0.001) and Group 4 (31%; p= 0.003). The global cost was 1,493€ (34€ -26,818€ ) and 
hospitalization was the main cost driver accounting for 85% of costs. The total cost 
per AHA class was: Group 1: 1,309€ ; Group 2: 1,880€ ; Group 3: 1,350€ ; Group 4: 1,330€ . 
When comparing ER-only vs. hospitalized: Group 1: 167€ vs. 4,105€ ; Group 2: 185€ 
vs. 2,583€ ; Group 3: 156€ vs. 2,278€ ; Group 4: 237€ vs. 3,734€ . Group 1 accounted for 
48% of overall costs, Group 2 40%, Groups 3 and 4, 6% each. Group 2 had the highest 
hospitalization rate (70.7%). ConClusions: AHA classes may contribute differently 
for costs associated with severe hypoglycemia. Insulin based therapy had the great-
est overall cost followed closely by secretagogue type drugs, which were associated 
with more hospitalizations.
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objeCtives: The aim of this study was to assess the burden of severe hypogly-
cemia (HYPO) and diabetes ketoacidosis (DKA) in terms of incidence, treatment 
patterns and cost in Italy. Methods: Eligible patients were identified through a 
data warehouse (DENALI), which matches with a probabilistic linkage demographic, 
clinical and economic data of about 9.9 million individuals of Lombardy region. The 
study population was made of all individuals with a diagnosis of type-1 diabetes 
(T1DM) who, during the period 1-1-2000 to 31-12-2010 developed a first episode of 
severe HYPO (ICD-9-CM: 251.0-251.2) or DKA (ICD-9-CM: 250.10-250.13) leading to 
hospitalization (index event). The identified individuals were followed-up from the 
index event to a maximum of 10 years. We evaluated demographic characteristics 
of the study population and costs (hospitalizations, drugs and outpatient exami-
nations/visits) from the National Health Service’s perspective. Results: During 
the observational period 1,321 T1DM subjects had at least one hospital admission 
for HYPO (27.5%) or DKA (72.5%) event. Median age (min-max) at the first HYPO 
or DKA event was 66.9 (1.3-96.7) and 39.4 (1.0-95.7) years, respectively. The overall 
mortality was 14.3 deaths/100 patient-years among HYPO subjects and 7.0 among 
DKA ones: the difference in mortality rates between groups disappeared once 
controlling for age. The mean costs with 95% C.I. (€ /patient-year) for HYPO and 
DKA patients were, respectively 10,442 (8,755-12,129) and 9,720 (8,659-10,782) in 
the event year, 10,296 (8,446-12,145) and 5,805 (4,539-7,071) in the year before the 
event, and 5,619 (3,841-7,398) and 4,974 (3,912-6,035) in the year after the event. 
Hospitalizations represented the driver of total costs: in the year of event and in the 
year after it varied from 70 to 56% and 76 to 60% for HYPO and DKA patients, respec-
tively. ConClusions: This study attempted to address the burden of severe T1DM 
HYPO and DKA events in Italy in an unselected population. The burden showed to 
be relevant in terms of incidence, mortality and costs.
DIaBetes/enDocrIne DIsorDers – Patient-reported outcomes & Patient 
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objeCtives: Sulfonylureas (SU) represent a common treatment for type 2 diabetes 
(T2DM), but they are associated with hypoglycemia, weight gain, and possibly car-
diovascular events. The purpose of this study is to evaluate factors associated with 
SU discontinuation after insulin initiation. Methods: Patients ≥ 21 years old with 
a T2DM diagnosis between 2005 and 2012 were identified using the GE electronic 
medical records database. Index date was defined as the first insulin prescription 
(Rx) between 2006 and 2011. Patients were required to be on SU at the index date. 
Patients were excluded if they did not have medical records available ≥ 12 months 
before and after index date, were receiving insulin in the 12 months prior to index 
date, or had other forms of diabetes. Treatment with other diabetes medications in 
addition to SU and insulin were permitted in this study. SU discontinuation occurred 
when the gap between the end date of current SU Rx supply and the start date of 
subsequent SU supply was ≥ 90 days apart. Multivariate logistic regression was 
performed to identify factors associated with SU discontinuation. Results: A total 
of 8,185 patients were selected, with mean age 64 years and 49% were male. 60.4% 
discontinued their SU Rxs within 1 year, with a median time from insulin initia-
tion to SU discontinuation of 88 days. In the logistic regression, baseline diagnosed 
hypoglycemia (OR= 2.29 [95% CI 1.03 - 5.10]; p= 0.04) and baseline HbA1c (OR= 1.04 
[1.01 - 1.06]; p= 0.004) were identified as factors associated with SU discontinuation. 
Additional factors included BMI (< 25 kg/m2 vs. ≥ 30 kg/m2; OR= 1.23 [1.03 - 1.46]; 
